Compare Northrop Grumman Corporation (NOC) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Northrop Grumman Corporation vs Revvity Inc — how do they compare? Northrop Grumman Corporation trades at $575.75 (market cap $81.78B), while Revvity Inc trades at $117.6 (market cap $12.91B). The key difference: Northrop Grumman Corporation is far larger — about 6.3× Revvity Inc's market cap, and Northrop Grumman Corporation pays the higher dividend (1.63%). Which is the better fit depends on your goals.
| NOC | RVTY | |
|---|---|---|
Market Cap | $81.78B | $12.91B |
Sector | Industrials | Technology |
52-Week High | $768.02 | $117.75 |
52-Week Low | $496.02 | $82.26 |
Enterprise Value | $95.77B | $15.23B |
Dividend Yield | 1.63% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Northrop Grumman (NOC) trades at $577.11, down 0.13% on the day, with a bullish technical trend supported by moving averages despite overbought RSI signals. The company reported strong Q2 2026 earnings, beating EPS estimates with a record $105 billion backlog, driven by defense contracts like the Sentinel program. Fundamentals show solid profitability with a 10.48% net income margin and 26.96% ROE, though valuation ratios like P/E of 18.3 are moderate. Recent news highlights a $3 billion missile-interceptor agreement, reinforcing growth prospects.
Outlook remains positive with analyst consensus favoring Buy (57% of ratings) and a $598.57 price target, implying ~4% upside. Key opportunities include sustained defense spending and backlog execution, while risks involve margin pressures from specific programs and geopolitical dependencies. The stock's proximity to its 52-week high suggests cautious optimism amid robust operational performance.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
